EP-7041 is a novel, potent, selective small molecule FXIa inhibitor designed to prevent thrombosis with limited risk for bleeding side effects. Results from the Phase 1a/1b study were highlighted in a poster presentation on Nov. 13 at the American Heart Association (AHA) Scientific Sessions 2017, in Anaheim, California.
eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.
Antithrombotic EP-7041 safe and well tolerated; performed in antithrombotic test range associated with clinical efficacy and with fast onset/offset of activity.
Phase 1a/1b Study of EP-7041: A Novel, Potent, Selective, Small Molecule FXIa Inhibitor
Phase 1 results suggest the PK/PD profile of EP-7041 is ideal in acute care hospital settings where patients are at risk of thromboembolic events.Download as PDF